FI2931265T6 - Muokattuja axl-peptidejä ja niiden käyttö axl-viestinvälityksen estossa etäispesäkkeitä estävässä hoidossa - Google Patents

Muokattuja axl-peptidejä ja niiden käyttö axl-viestinvälityksen estossa etäispesäkkeitä estävässä hoidossa Download PDF

Info

Publication number
FI2931265T6
FI2931265T6 FIEP13862780.7T FI13862780T FI2931265T6 FI 2931265 T6 FI2931265 T6 FI 2931265T6 FI 13862780 T FI13862780 T FI 13862780T FI 2931265 T6 FI2931265 T6 FI 2931265T6
Authority
FI
Finland
Prior art keywords
axl
variant polypeptide
inhibitor
seq
soluble axl
Prior art date
Application number
FIEP13862780.7T
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Inventor
Amato J Giaccia
Erinn Bruno Rankin
Jennifer R Cochran
Douglas Jones
Mihalis Kariolis
Katherine Fuh
Yu Miao
Susan Hershenson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50934967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI2931265(T6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Application granted granted Critical
Publication of FI2931265T6 publication Critical patent/FI2931265T6/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FIEP13862780.7T 2012-12-14 2013-12-12 Muokattuja axl-peptidejä ja niiden käyttö axl-viestinvälityksen estossa etäispesäkkeitä estävässä hoidossa FI2931265T6 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261737276P 2012-12-14 2012-12-14
PCT/US2013/074786 WO2014093690A1 (en) 2012-12-14 2013-12-12 Modified axl peptides and their use in inhibition of axl signaling in anti-metastatic therapy

Publications (1)

Publication Number Publication Date
FI2931265T6 true FI2931265T6 (fi) 2023-05-23

Family

ID=50934967

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP13862780.7T FI2931265T6 (fi) 2012-12-14 2013-12-12 Muokattuja axl-peptidejä ja niiden käyttö axl-viestinvälityksen estossa etäispesäkkeitä estävässä hoidossa

Country Status (11)

Country Link
US (3) US9822347B2 (enExample)
EP (2) EP2931265B3 (enExample)
JP (2) JP6345690B2 (enExample)
AU (3) AU2013359179B2 (enExample)
CA (1) CA2894539C (enExample)
DK (2) DK3326622T3 (enExample)
ES (2) ES2665323T7 (enExample)
FI (1) FI2931265T6 (enExample)
NO (1) NO3049208T3 (enExample)
PT (2) PT2931265T (enExample)
WO (1) WO2014093690A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9074192B2 (en) * 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
CA2786149C (en) * 2010-01-22 2019-11-12 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl signaling in anti-metastatic therapy
US9879061B2 (en) 2011-12-15 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
PT2931265T (pt) 2012-12-14 2018-04-16 Univ Leland Stanford Junior Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática
US10137173B2 (en) 2014-10-20 2018-11-27 Aravive Biologics, Inc. Antiviral activity of Gas6 inhibitor
CA2971406A1 (en) * 2014-12-18 2016-06-23 Aravive Biologics, Inc. Antifibrotic activity of gas6 inhibitor
KR20200085307A (ko) * 2017-11-04 2020-07-14 아라바이브 바이올로직스, 인크. Axl 유인 수용체를 이용한 전이성 암의 치료 방법
AU2022343188A1 (en) * 2021-09-11 2024-05-02 Aravive Inc Methods of treating locally advanced or metastatic pancreatic adenocarcinoma using axl decoy receptors as first-line therapy

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5538861A (en) * 1994-07-29 1996-07-23 Amgen Inc. DNA encoding a stimulating factor for the axl receptor
US20030032103A1 (en) 1997-09-18 2003-02-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
WO2004108748A2 (en) 2002-09-24 2004-12-16 Dow, Kenneth, Centocor, Inc. Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses
AU2004231036A1 (en) 2003-04-18 2004-10-28 Novartis Ag Methods and compositions targeting tyrosine kinases for the diagnosis and treatment of osteoarthritis
JP2005278631A (ja) 2004-03-04 2005-10-13 National Institute Of Advanced Industrial & Technology Ａｘｌリガンド結合領域蛋白質、その製造方法及びそれを用いたスクリーニング方法
US20080267975A1 (en) 2004-11-24 2008-10-30 The Regents Of The University Of Colorado Mer Diagnostic and Therapeutic Agents
EP2177614B1 (en) 2005-05-02 2014-12-31 Toray Industries, Inc. Composition and method for diagnosing esophageal cancer and metastasis of esophageal cancer
EP2114983B8 (en) 2007-02-07 2015-02-18 The Regents of the University of Colorado, A Body Corporate Axl tyrosine kinase inhibitors and methods of making and using the same
CA2682733A1 (en) 2007-04-13 2008-10-23 Supergen, Inc. Axl kinase inhibitors
WO2009005813A1 (en) 2007-07-02 2009-01-08 Wyeth Modulators of axl for use in treating bone disorders
US20120230991A1 (en) * 2008-07-29 2012-09-13 Douglas Kim Graham Methods and compounds for enhancing anti-cancer therapy
CN102257001A (zh) * 2008-12-19 2011-11-23 诺瓦提斯公司 治疗自体免疫和炎性病症的可溶性多肽
MX2011011825A (es) * 2009-05-11 2011-12-06 U3 Pharma Gmbh Anticuerpos humanizados para axl.
CA2786149C (en) 2010-01-22 2019-11-12 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl signaling in anti-metastatic therapy
US9074192B2 (en) 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
WO2012064658A1 (en) 2010-11-08 2012-05-18 The Board Of Trustees Of The Leland Stanford Junior University Fusion proteins comprising an engineered knottin peptide and uses thereof
US9879061B2 (en) 2011-12-15 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
PT2931265T (pt) 2012-12-14 2018-04-16 Univ Leland Stanford Junior Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática
US20150315552A1 (en) 2012-12-14 2015-11-05 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL Signaling in Primary Tumor Therapy
WO2015030849A1 (en) * 2013-08-30 2015-03-05 The Board Of Trustees Of The Leland Stanford Junior University High-affinity binding to gas6
US10137173B2 (en) * 2014-10-20 2018-11-27 Aravive Biologics, Inc. Antiviral activity of Gas6 inhibitor
CA2971406A1 (en) * 2014-12-18 2016-06-23 Aravive Biologics, Inc. Antifibrotic activity of gas6 inhibitor

Also Published As

Publication number Publication date
AU2017272193A1 (en) 2017-12-21
AU2013359179B2 (en) 2017-10-05
EP3326622A1 (en) 2018-05-30
US20220220458A1 (en) 2022-07-14
EP2931265B3 (en) 2023-04-05
AU2019210662B2 (en) 2021-07-01
CA2894539C (en) 2021-09-28
JP6832887B2 (ja) 2021-02-24
DK2931265T3 (en) 2018-04-16
ES2665323T3 (es) 2018-04-25
US20150315553A1 (en) 2015-11-05
CA2894539A1 (en) 2014-06-19
US11136563B2 (en) 2021-10-05
ES2862335T3 (es) 2021-10-07
PT3326622T (pt) 2021-04-07
ES2665323T7 (es) 2023-06-15
DK2931265T6 (da) 2023-05-01
HK1256071A1 (en) 2019-09-13
US20180030422A1 (en) 2018-02-01
WO2014093690A1 (en) 2014-06-19
AU2019210662A1 (en) 2019-08-22
JP6345690B2 (ja) 2018-06-20
JP2018154641A (ja) 2018-10-04
NO3049208T3 (enExample) 2018-04-14
JP2016510309A (ja) 2016-04-07
DK3326622T3 (da) 2021-04-06
EP2931265B1 (en) 2018-01-31
AU2013359179A1 (en) 2015-07-02
PT2931265T (pt) 2018-04-16
EP2931265A4 (en) 2016-08-31
US9822347B2 (en) 2017-11-21
EP2931265A1 (en) 2015-10-21
EP3326622B1 (en) 2021-01-20

Similar Documents

Publication Publication Date Title
FI2931265T6 (fi) Muokattuja axl-peptidejä ja niiden käyttö axl-viestinvälityksen estossa etäispesäkkeitä estävässä hoidossa
JP2012082206A5 (enExample)
RU2011141522A (ru) Антиангиогенные слитые белки
IN2012DN03368A (enExample)
WO2011036442A3 (en) Thrombin c- terminal polypeptides and uses thereof for treating inflammation coagulation disorders
MX2014000210A (es) Peptidos procoagulantes y sus derivados, y usos para estos.
NZ597306A (en) Mesenchymal stem cell differentiation
JP2017160222A5 (enExample)
AR065289A1 (es) Antagonistas de activina - actriia y sus usos para la promocion del crecimiento oseo y el tratamiento de mieloma multiple
PH12014501083A1 (en) Anticancer fusion protein
NZ602845A (en) Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
UA110599C2 (uk) Пептид для імунотерапії пухлин, включаючи нейрональні пухлини та пухлини мозку
WO2013151672A3 (en) Modified polynucleotides for the production of oncology-related proteins and peptides
RU2015119517A (ru) Новый способ лечения инфаркта миокарда с применением фрагмента hmgb1
JP2015524403A5 (enExample)
HRP20150664T1 (hr) Antikancerogeni fuzijski protein
WO2013013085A3 (en) Anti-fibrotic peptides and their use in methods for treating diseases and disorders characterized by fibrosis
WO2016004906A3 (zh) 一种肿瘤血管阻断剂多肽、基因、表达载体及其应用
NZ610620A (en) Inhibitors of apoptosis and uses thereof
MX352796B (es) Proteina de fusion anticancerigena.
WO2013096868A3 (en) Saposin-a derived peptides and uses thereof
JP5992529B2 (ja) ポリペプチド、足場組成物、軟骨組織修復用組成物、軟骨細胞培養用組成物及びグリコサミノグリカン産生促進用組成物